Cartesian Stock Price, News & Analysis

Cartesian Therapeutics (NASDAQ: RNAC) announced that Carsten Brunn, Ph.D., currently President and CEO, was named Chairman of the Board effective October 29, 2025.

Dr. Brunn succeeds Carrie S. Cox, who is stepping down to focus on other responsibilities, including a recent appointment as Executive Chair of another publicly traded company. In connection with the change, Patrick Zenner, M.B.A. was named Lead Independent Director.

The company highlighted progress advancing Descartes-08 toward its first planned regulatory submission and referenced the board leadership transition as part of its corporate governance updates.

Cartesian Therapeutics (NASDAQ: RNAC) announced an employment inducement grant for one new employee on Oct 2, 2025. The company issued an option for 9,700 shares with an exercise price of $10.34 (Nasdaq close on grant date). The option was approved by the board and granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement award.

The option vests 25% on Oct 2, 2026, then in three equal annual installments, becoming fully vested on Oct 2, 2029, and carries a 10-year term.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on cell therapy for autoimmune diseases, has announced its participation in three major healthcare investor conferences in September 2025.

The company will participate in the Cantor Global Healthcare Conference on September 4, the Morgan Stanley Healthcare Conference on September 9, and the H.C. Wainwright Global Investment Conference on September 10. All presentations will be available via webcast on the company's website.

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2025 financial results and provided key pipeline updates. The company has initiated its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with the first participant enrolled in May 2025. The trial will evaluate the therapy versus placebo in approximately 100 participants.

The company maintains a strong financial position with $162.1 million in cash and equivalents as of June 30, 2025, expected to fund operations into mid-2027. Q2 2025 saw a net income of $15.9 million ($0.51 per share). Cartesian anticipates preliminary data from its Phase 2 trial of Descartes-08 in systemic lupus erythematosus and plans to initiate a pediatric basket trial in select autoimmune indications in 2H25.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to two new employees. The company issued stock options to purchase 5,750 shares at an exercise price of $12.48 per share on August 4, 2025.

The options were granted under the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan with a four-year vesting schedule. The initial 25% vests on August 4, 2026, followed by three equal annual installments, becoming fully vested by August 4, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4).

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, has granted employment inducement awards to three new employees. The company issued stock options totaling 26,350 shares with an exercise price of $9.98, matching the closing price on Nasdaq Global Market on June 2, 2025. These options, granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan, will vest 25% on June 2, 2026, followed by three equal annual installments until full vesting on June 2, 2029. The options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Cartesian Therapeutics (NASDAQ: RNAC) has initiated its Phase 3 AURORA trial for Descartes-08, enrolling the first participant to treat myasthenia gravis (MG). Descartes-08 is an autologous CAR-T cell therapy targeting BCMA, designed for outpatient administration without preconditioning chemotherapy. The Phase 3 trial will evaluate Descartes-08 against placebo in approximately 100 AChR Ab+ MG patients. Previous Phase 2b results showed promising efficacy, with patients experiencing an average 4.8-point reduction in MG-ADL scores at 12 months. Notably, treatment-naive patients showed even better results with a 7.1-point reduction, and 57% maintained minimum symptoms at 12 months. The AURORA trial's primary endpoint will measure the proportion of participants achieving a ≥3-point improvement in MG-ADL score at Month 4 compared to placebo.

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. The company's management will participate in a fireside chat, which will be available via live webcast on Cartesian's website. An archived replay will also be accessible for a limited time in the Events section at www.cartesiantherapeutics.com.

Cartesian Therapeutics (NASDAQ: RNAC) reported its Q1 2025 financial results and provided significant pipeline updates. The company's lead candidate Descartes-08 showed promising Phase 2b results in myasthenia gravis (MG), with sustained benefits through 12 months after a single course of therapy. Notably, patients without prior biologic exposure showed an average 7.1-point reduction in MG-ADL, with 57% maintaining minimum symptoms at Month 12.

The company plans to initiate the Phase 3 AURORA trial for Descartes-08 in MG in Q2 2025. Additional milestones expected in H2 2025 include preliminary data from a Phase 2 trial in systemic lupus erythematosus and initiation of a pediatric basket trial. Financially, Cartesian reported $182.1 million in cash and equivalents as of March 31, 2025, expected to fund operations into mid-2027. Q1 2025 net loss was $(17.7) million, or $(0.68) per share.